Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Properties of Oral AT-406 in Combination With Daunorubicin and Cytarabine in Patients With Poor-risk Acute Myelogenous Leukemia (AML)
Clinical trial NCT01265199 · TERMINATED
Trial details
- NCT number
- NCT01265199
- Sponsor
- Ascenta Therapeutics
- Status
- TERMINATED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2011-02-01
- Primary completion
- 2013-01-01
- Enrollment
- 29
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.